<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04550715</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00177625</org_study_id>
    <secondary_id>UG3DA050173</secondary_id>
    <nct_id>NCT04550715</nct_id>
  </id_info>
  <brief_title>Prevention Interventions for Opioid Misuse</brief_title>
  <official_title>Optimized Interventions to Prevent Opioid Use Disorder Among Adolescents and Young Adults in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to develop and test innovative interventions to prevent the&#xD;
      development of opioid misuse and opioid use disorders among older adolescents and young&#xD;
      adults (AYA; ages 16-30) who use opioids, which will be initiated from a health care visit in&#xD;
      the emergency department and extended post discharge via a telehealth approach. This study&#xD;
      will have significant impact by identifying optimal, cost-effective opioid prevention&#xD;
      strategies to sustain outcomes among AYAs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in opioid misuse</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Alcohol Smoking and Substance Involvement Screening Test severity score (prescription opioids/heroin, scores range 0-27 per subscale, higher score indicates worse outcomes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in days of opioid misuse</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Addiction Severity Index (modified; score ranges from 0-30, higher score indicates worse outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overdose risk behaviors</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Opioid-related risk behaviors (score ranges from 0-32, higher score indicates worse outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in other drug and alcohol use</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Substance use index (based on frequency measures, higher scores indicate worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in substance use consequences</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Adapted alcohol, cannabis, and/or opioid-related consequences (total, higher score indicates worse outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in impaired driving</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Adapted items from Young Adult Driving Questionnaire (5 items; score ranges from 0-30; higher score indicates worse outcome)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1280</enrollment>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Brief intervention (BI) then Portal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The BI will be delivered at intake and the portal will occur for 4 weeks starting at intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brief intervention (BI) then Enhanced Usual Care (EUC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The BI will be delivered at intake and EUC will be added 4 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Usual Care (EUC) then Portal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EUC will be delivered at intake and the portal will occur for 4 weeks starting at intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Usual Care (EUC) then EUC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EUC will be delivered at intake and delivered again 4 weeks later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief intervention (BI)</intervention_name>
    <description>A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.</description>
    <arm_group_label>Brief intervention (BI) then Enhanced Usual Care (EUC)</arm_group_label>
    <arm_group_label>Brief intervention (BI) then Portal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Portal</intervention_name>
    <description>Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.</description>
    <arm_group_label>Brief intervention (BI) then Portal</arm_group_label>
    <arm_group_label>Enhanced Usual Care (EUC) then Portal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced Usual Care (EUC)</intervention_name>
    <description>The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.</description>
    <arm_group_label>Brief intervention (BI) then Enhanced Usual Care (EUC)</arm_group_label>
    <arm_group_label>Enhanced Usual Care (EUC) then EUC</arm_group_label>
    <arm_group_label>Enhanced Usual Care (EUC) then Portal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 16-30 years&#xD;
&#xD;
          -  Seeking care in Michigan Medicine emergency department (ED)&#xD;
&#xD;
          -  Ability to read/comprehend and communicate in English&#xD;
&#xD;
          -  Medically &amp; cognitively able to provide consent or assent&#xD;
&#xD;
          -  Prescription opioid use plus &gt;=1 other risk factor (misuse positive for marijuana,&#xD;
             other illicit drugs, other prescription drug misuse; binge drinking; depression or&#xD;
             suicidality) or opioid misuse [prescription opioid misuse or illicit opioid use (e.g.,&#xD;
             heroin, fentanyl)]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presenting with acute sexual assault, acute suicidality or a current cancer&#xD;
             diagnosis/are currently receiving cancer treatment&#xD;
&#xD;
          -  Current pregnancy at baseline&#xD;
&#xD;
          -  History of injection drug use within last 12 months&#xD;
&#xD;
          -  High risk for opioid use disorder&#xD;
&#xD;
          -  Enrolled in Aim 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maureen Walton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erin Bonar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meredith Kotov</last_name>
    <phone>734-232-0361</phone>
    <email>mphilyaw@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Bourque</last_name>
    <email>csmolens@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Maureen A Walton</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>opioid misuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

